Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04783935
Registration number
NCT04783935
Ethics application status
Date submitted
3/03/2021
Date registered
5/03/2021
Date last updated
22/01/2025
Titles & IDs
Public title
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Query!
Scientific title
A 2-year Extension Study to Evaluate Long-term Effectiveness of Mavenclad® in Participants Who Have Completed Trial MS700568_0022 (MAGNIFY MS) (Magnify MS Extension)
Query!
Secondary ID [1]
0
0
2020-003995-42
Query!
Secondary ID [2]
0
0
MS700568_0157
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Sclerosis
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Mavenclad®
Experimental: Mavenclad® -
Treatment: Drugs: Mavenclad®
No intervention was administered as a part of this study. Participants who had received Mavenclad® up to 2 years (Year 1 and 2) in the parent study MS700568_0022 (NCT03364036) were enrolled into this extension study and will be assessed up to 2 years follow-up (Year 3 and 4).
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) During Year 3 to 4
Query!
Assessment method [1]
0
0
The definition of NEDA-3 encompasses a combination of the following 3 related measures of disease activity: No relapses, no confirmed disability progression sustained for 12 weeks as measured on EDSS, and no magnetic resonance imaging (MRI) disease activity, defined as no gadolinium-enhancing (GdE) lesions and no new or enlarging T2 lesions. NEDA-3 was analyzed with the Kaplan-Meier (KM) time-to-event method to reduce the impact of unknown/missing information. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. An EDSS progression was defined as an increase of the EDSS score of at least 1.5 point compared to baseline for participants with a baseline EDSS of 0. For participants with an EDSS score between 0.5 and 4.5 at baseline (SD1), EDSS progression was defined as an increase of at least 1 point. For participants with baseline EDSS score of 5, EDSS progression was defined as an increase of at least 0.5.
Query!
Timepoint [1]
0
0
Year 3 to 4 after the initial dose of Mavenclad® tablets in parent study
Query!
Secondary outcome [1]
0
0
Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) at Year 3 and at Year 4
Query!
Assessment method [1]
0
0
The definition of NEDA-3 encompasses a combination of the following 3 related measures of disease activity: No relapses, no confirmed disability progression sustained for 12 weeks as measured on EDSS, and no magnetic resonance imaging (MRI) disease activity, defined as no gadolinium-enhancing (GdE) lesions and no new or enlarging T2 lesions. NEDA-3 was analyzed with the Kaplan-Meier (KM) time-to-event method to reduce the impact of unknown/missing information. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. An EDSS progression was defined as an increase of the EDSS score of at least 1.5 point compared to baseline for participants with a baseline EDSS of 0. For participants with an EDSS score between 0.5 and 4.5 at baseline (SD1), EDSS progression was defined as an increase of at least 1 point. For participants with baseline EDSS score of 5, EDSS progression was defined as an increase of at least 0.5.
Query!
Timepoint [1]
0
0
At Year 3 and 4 after the initial dose of Mavenclad® tablets in parent study
Query!
Secondary outcome [2]
0
0
Percentage of Participants With No Evidence of Disease Activity (Three Parameter [NEDA-3]) After the Start of Study Medication During the Parent Study Until the End of Year 3 and Year 4
Query!
Assessment method [2]
0
0
The definition of NEDA-3 encompasses a combination of the following 3 related measures of disease activity: No relapses, no confirmed disability progression sustained for 12 weeks as measured on EDSS, and no magnetic resonance imaging (MRI) disease activity, defined as no gadolinium-enhancing (GdE) lesions and no new or enlarging T2 lesions. NEDA-3 was analyzed with the Kaplan-Meier (KM) time-to-event method to reduce the impact of unknown/missing information. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. An EDSS progression was defined as an increase of the EDSS score of at least 1.5 point compared to baseline for participants with a baseline EDSS of 0. For participants with an EDSS score between 0.5 and 4.5 at baseline (SD1), EDSS progression was defined as an increase of at least 1 point. For participants with baseline EDSS score of 5, EDSS progression was defined as an increase of at least 0.5.
Query!
Timepoint [2]
0
0
After the initial dose of Mavenclad® tablets in parent study until the end of Year 3 and 4
Query!
Secondary outcome [3]
0
0
Percentage of Participants Remaining Three Parameter No Evidence of Disease Activity (NEDA-3) During Year 3 or 4 Among Those With NEDA-3 During Year 1 or 2
Query!
Assessment method [3]
0
0
The definition of NEDA-3 encompasses a combination of the following 3 related measures of disease activity: No relapses, no confirmed disability progression sustained for 12 weeks as measured on EDSS, and no magnetic resonance imaging (MRI) disease activity, defined as no gadolinium-enhancing (GdE) lesions and no new or enlarging T2 lesions. NEDA-3 was analyzed with the Kaplan-Meier (KM) time-to-event method to reduce the impact of unknown/missing information. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. An EDSS progression was defined as an increase of the EDSS score of at least 1.5 point compared to baseline for participants with a baseline EDSS of 0. For participants with an EDSS score between 0.5 and 4.5 at baseline (SD1), EDSS progression was defined as an increase of at least 1 point. For participants with baseline EDSS score of 5, EDSS progression was defined as an increase of at least 0.5.
Query!
Timepoint [3]
0
0
At Year 3 and 4 after the initial dose of Mavenclad® tablets in parent study
Query!
Secondary outcome [4]
0
0
Time to First Disease Activity During Extension Study Period
Query!
Assessment method [4]
0
0
Time to first disease activity is defined as the time to first occurrence of either qualifying relapse, or 6-month confirmed disability progression (6mCDP), or new or enlarging T2-hyperintense lesions (active T2 lesions), or new T1 Gd+ lesions. The 6MCDP during Extension Study Period is defined as sustained increase in EDSS score that started during the Period. Six-month CDP was considered.
Query!
Timepoint [4]
0
0
From Month 24 after the initial dose of Mavenclad tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [5]
0
0
Time to First Disease Activity During up to Parent and Extension Study Period (4 Years)
Query!
Assessment method [5]
0
0
Time to first disease activity is defined as the time to first occurrence of either qualifying relapse, or 6MCDP, or new or enlarging T2-hyperintense lesions (active T2 lesions), or new T1 Gd+ lesions. The 6MCDP during Extension Study Period is defined as sustained increase in EDSS score that started during the Period. Six-month CDP was considered.
Query!
Timepoint [5]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [6]
0
0
Time to First New or Enlarging T2 Lesion During Extension Study Period
Query!
Assessment method [6]
0
0
Time taken for newly enlarging T2 lesions to show up is measured by follow-up MRI.
Query!
Timepoint [6]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [7]
0
0
Time to First New T1 Gadolinium Enhancing (Gd+) Lesion During Parent and Extension Study Period
Query!
Assessment method [7]
0
0
Time taken for newly enlarging T1 Gadolinium Enhancing (Gd+) Lesion to show up is measured by follow-up MRI. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [7]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [8]
0
0
Time to First Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS) During Parent and Extension Study Period
Query!
Assessment method [8]
0
0
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. An EDSS progression was defined as an increase of the EDSS score of at least 1.5 point compared to baseline for participants with a baseline EDSS of 0. For participants with an EDSS score between 0.5 and 4.5 at baseline (SD1), EDSS progression was defined as an increase of at least 1 point. For participants with baseline EDSS score of 5, EDSS progression was defined as an increase of at least 0.5. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [8]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [9]
0
0
Time to First Qualifying Relapse During Parent and Extension Study Period
Query!
Assessment method [9]
0
0
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [9]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [10]
0
0
Time to Recurrent Qualifying Relapse During Parent and Extension Study Period
Query!
Assessment method [10]
0
0
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [10]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [11]
0
0
Time to Treatment Start With Other Disease Modifying Drugs (DMDs) During Parent and Extension Study Period
Query!
Assessment method [11]
0
0
Time to Treatment Start with Other Disease Modifying Drugs (DMDs) During Parent and Extension Study Period. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [11]
0
0
From the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 4 years)
Query!
Secondary outcome [12]
0
0
Time to First New or Enlarging T2 Lesion During Extension Study Period
Query!
Assessment method [12]
0
0
Time taken for newly enlarging T2 Gadolinium Enhancing (Gd+) Lesion to show up is measured by follow-up MRI. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [12]
0
0
From Month 24 after the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [13]
0
0
Time to First New T1 Gadolinium Enhancing (Gd+) Lesion During Extension Study Period
Query!
Assessment method [13]
0
0
Time taken for newly enlarging T1 Gadolinium Enhancing (Gd+) Lesion to show up is measured by follow-up MRI. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [13]
0
0
From Month 24 after the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [14]
0
0
Time to First Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS) During Extension Study Period
Query!
Assessment method [14]
0
0
The EDSS is an ordinal clinical rating scale in half-point increments. It assesses the following eight functional systems, areas of the central nervous system that control bodily functions: Pyramidal (ability to walk), Cerebellar (coordination), Brain stem (speech and swallowing), Sensory (touch and pain), Bowel and bladder functions, Visual, Mental, Other (includes any other neurological findings due to Multiple Sclerosis \[MS\]). EDSS overall score ranging from 0 (normal) to 10 (death due to MS). The 6MCDP during Extension Study Period is defined as sustained increase in EDSS score that started during the Period. Six-month CDP was considered.
Query!
Timepoint [14]
0
0
From Month 24 after the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [15]
0
0
Time to First Qualifying Relapse During Extension Study Period
Query!
Assessment method [15]
0
0
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [15]
0
0
From Month 24 after the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [16]
0
0
Time to Recurrent Qualifying Relapse During Extension Study Period
Query!
Assessment method [16]
0
0
A qualifying relapse is defined as new, worsening or recurrent neurological symptoms attributed to Multiple Sclerosis (MS) that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.
Query!
Timepoint [16]
0
0
From Month 24 after the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [17]
0
0
Time to Treatment Start With Other Disease Modifying Drugs (DMDs) During Extension Study Period
Query!
Assessment method [17]
0
0
Time to Treatment Start with Other Disease Modifying Drugs (DMDs) During Parent and Extension Study Period. Kaplan - Meier estimates were used for calculation of data.
Query!
Timepoint [17]
0
0
From Month 24 after the initial dose of Mavenclad® tablets in parent study until the end of extension study (approximately 2 years)
Query!
Secondary outcome [18]
0
0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [18]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a participant. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a study intervention. A serious adverse event (SAE) was any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.
Query!
Timepoint [18]
0
0
From Month 24 after the initial dose of Mavenclad tablets in parent study until the end of extension study (approximately 2 years)
Query!
Eligibility
Key inclusion criteria
* Participants of the MAGNIFY Multiple Sclerosis (MS) trial who received at least a single dose of cladribine tablets during the MAGNIFY MS trial and data on Magnetic resonance imaging (MRI) is available/acquired from at least parent study Month 18 or Month 24 visit and Expanded Disability Status Scale (EDSS) and relapse from parent study Month 24 visit
* Capable of giving signed informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
* Participation in other studies/trials
Query!
Study design
Purpose of the study
Other
Query!
Allocation to intervention
Not applicable
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/03/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
21/09/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
219
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [2]
0
0
John Hunter Hospital - New Lambton
Query!
Recruitment postcode(s) [1]
0
0
- Liverpool
Query!
Recruitment postcode(s) [2]
0
0
- New Lambton
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Klagenfurt
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Salzburg
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
Edmonton
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
London
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Montreal
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Vancouver
Query!
Country [7]
0
0
Czechia
Query!
State/province [7]
0
0
Brno
Query!
Country [8]
0
0
Czechia
Query!
State/province [8]
0
0
Hradec Kralove
Query!
Country [9]
0
0
Czechia
Query!
State/province [9]
0
0
Pardubice
Query!
Country [10]
0
0
Czechia
Query!
State/province [10]
0
0
Praha 5
Query!
Country [11]
0
0
Finland
Query!
State/province [11]
0
0
Tampere
Query!
Country [12]
0
0
Finland
Query!
State/province [12]
0
0
Turku
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Montpellier
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Nice
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Nimes
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Poissy Cedex
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Rennes Cedex 9
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Strasbourg Cedex
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Dresden
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Essen
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Hamburg
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Hannover
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Leipzig
Query!
Country [24]
0
0
Hungary
Query!
State/province [24]
0
0
Szeged
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Ashkelon
Query!
Country [26]
0
0
Israel
Query!
State/province [26]
0
0
Haifa
Query!
Country [27]
0
0
Israel
Query!
State/province [27]
0
0
Tel-Hashomer
Query!
Country [28]
0
0
Italy
Query!
State/province [28]
0
0
Chieti
Query!
Country [29]
0
0
Italy
Query!
State/province [29]
0
0
Napoli
Query!
Country [30]
0
0
Italy
Query!
State/province [30]
0
0
Pozzilli
Query!
Country [31]
0
0
Poland
Query!
State/province [31]
0
0
Katowice
Query!
Country [32]
0
0
Poland
Query!
State/province [32]
0
0
Lublin
Query!
Country [33]
0
0
Poland
Query!
State/province [33]
0
0
Zabrze
Query!
Country [34]
0
0
Spain
Query!
State/province [34]
0
0
Baracaldo
Query!
Country [35]
0
0
Spain
Query!
State/province [35]
0
0
Castilleja de la Cuesta
Query!
Country [36]
0
0
Spain
Query!
State/province [36]
0
0
Madrid
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Majadahonda
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Valencia
Query!
Country [39]
0
0
Sweden
Query!
State/province [39]
0
0
Göteborg
Query!
Country [40]
0
0
Sweden
Query!
State/province [40]
0
0
Stockholm
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
Birmingham
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Cardiff
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary purpose of this study was to evaluate the long-term effectiveness of Mavenclad® tablets, in terms of disease activity and safety, in participants with highly-active relapsing multiple sclerosis (RMS) previously participating in the MAGNIFY MS trial MS700568_0022 (NCT03364036).
Query!
Trial website
https://clinicaltrials.gov/study/NCT04783935
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Responsible
Query!
Address
0
0
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/35/NCT04783935/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/35/NCT04783935/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT04783935
Download to PDF